Ozempic
Also known as: Semaglutide injection, Ozempic pen
Ozempic is the brand name for semaglutide, a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk and FDA-approved for type 2 diabetes management. It has become one of the most prescribed medications worldwide for glycemic control.
Last updated: January 28, 2026
What is Ozempic?
Ozempic is the brand name for semaglutide when prescribed for type 2 diabetes. It is manufactured by Novo Nordisk and was first approved by the FDA in December 2017. The medication is administered once weekly via subcutaneous injection using a pre-filled pen device.
Key facts:
- Generic name: Semaglutide
- Manufacturer: Novo Nordisk
- FDA approval: December 2017 (type 2 diabetes)
- Administration: Weekly subcutaneous injection
- Doses available: 0.25 mg, 0.5 mg, 1 mg, 2 mg
How Ozempic Works
Ozempic works by mimicking the GLP-1 hormone, which is naturally released after eating. This leads to:
- Increased insulin secretion — Only when blood sugar is elevated
- Reduced glucagon release — Decreases liver glucose production
- Slowed gastric emptying — Food moves more slowly through the stomach
- Reduced appetite — Acts on brain centers controlling hunger
Ozempic vs Wegovy
Ozempic and Wegovy contain the same active ingredient (semaglutide) but are approved for different uses:
| Aspect | Ozempic | Wegovy |
|---|---|---|
| Indication | Type 2 diabetes | Chronic weight management |
| Maximum dose | 2 mg weekly | 2.4 mg weekly |
| Target A1C reduction | Primary goal | Secondary benefit |
| Insurance coverage | Often covered for T2D | Variable for weight loss |
Clinical Evidence
Ozempic’s approval was based on the SUSTAIN clinical trial program:
| Trial | Key Finding |
|---|---|
| SUSTAIN-6 | Cardiovascular safety confirmed |
| SUSTAIN 1-10 | A1C reductions of 1.0-1.8% |
| SELECT (2023) | 20% cardiovascular risk reduction |
Common Side Effects
The most frequently reported side effects include:
- Nausea (especially during dose escalation)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Most gastrointestinal side effects diminish over time with continued use.
Important Safety Information
Ozempic carries a black box warning for thyroid C-cell tumor risk based on rodent studies. It is contraindicated in patients with:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
Regulatory Status
| Region | Status |
|---|---|
| USA (FDA) | Approved (T2D) |
| EU (EMA) | Approved |
| UK (MHRA) | Approved |
| Japan | Approved |
This entry is for educational purposes only. Ozempic is a prescription medication. Consult a healthcare provider for medical advice.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.